Integration expenses, lower revenues, higher R&D spending and rising corporate costs impact PPD in Q1, but cancellations back to normal levels and requests for proposals increase.
The Chinese government is supporting a $100m (€73m) project to build a contract biologics production facility in Beijing, which, by some measures, would be the largest in Asia.
There are signs that 2010 will be a better year for the fine and custom chemistry industry but companies at Informex remained cautious and are planning accordingly.
US software firm Instem will establish an office in Shanghai, China, to provide customer support, client management, development and sales support to its Chinese pharmaceutical and life sciences R&D clients.
Shanghai The First Biochemical & Pharmaceutical Company has installed Praxair China’s NCOOL cryogenic heat exchanger, becoming the first company to sign this sort of liquid nitrogen supply contract.
India and China share many similarities as outsourcing locations but there are also significant differences that are important to understand before making a commitment, according to a report.
Novozymes Biopharma is building a new Bacillus-based hyaluronic acid (bHA) production facility in China to meet “increasing demand” for the substance that has drug delivery applications.
Construction of a new stem cell research and processing plant began yesterday in China’s Eastern Jiangsu province as part of a joint project between the Chinese government and Shenzen Beike Biotechnology.
Sinobiopharma is seeking a Chinese patent covering the manufacture of capsule forms of the heart drug perindopril, claiming it is the first company in the world to produce the medication in this easy to swallow format.
Although the downturn has slowed Big Pharma’s investment in China, the country’s wide ranging healthcare reforms and changing economic landscape still provide considerable opportunities says PricewaterhouseCoopers (PwC).
Researchers believe they have found “more promising” sources of shikimic acid, a precursor in the production of Tamiflu, shortages of which have previously caused bottlenecks in producing the bird flu vaccine.
SGS Life Science Services opened a new microbiology testing laboratory in Shanghai, China to offer cGMP compliant API testing services for method development and validation.
Sinovac’s recently opened vaccine filling and packaging facility in Beijing, China has received SFDA GMP certification, which the firm says will increase production capacity to around 40m doses a year.
A new report suggests the large numbers of fake drugs produced in China could drive CMO customers away and see Central and Eastern Europe (CEE) emerge as a contract manufacturing hotbed.
Pfizer has enlisted outsourcing services firm NovaMed
Pharmaceuticals to conduct the distribution, sales and marketing of
some of its products in the country.
Cordium Links has partnered with an unnamed Chinese firm to bring
electrocardiogram (ECG) laboratory services to companies performing
cardiac safety evaluation as part of clinical research in China -
claiming to be the first firm...
Europe's Novasecta has formed an alliance with Chinese contract
research organisations (CROs) Sundia Meditech and HD BioSciences to
provide their R&D services to European mid-sized biopharma
firms.
Product recalls in the UK due to health and safety concerns have
shot up to their highest level, with the rise in outsourcing to
China finger pointed for much of the blame.
US-based MPI Research and China's Shanghai Medicilon have formed a
joint venture in preclinical services, as they position themselves
to cash in on what is a budding market sector in China.
The first steps in tightening the safety controls on the
pharmaceutical ingredients imported to the US from China have been
taken following months of negotiations between the regulatory
bodies of the two countries.
Chinese drug manufacturers could be given a 24-hour deadline by
regulators to pull unsafe pharmaceuticals off the market or face a
fine, a Chinese newspaper reported.
WuXi PharmaTech, the biggest Chinese contract research organisation
(CRO), has put an end to weeks of speculation by officially
announcing it plans an initial public offering (IPO) on the New
York Stock Exchange.
The former director of the country's State Food and Drug
Administration (SFDA) has lodged an appeal against the death
penalty slapped on him after a corruption conviction.
China is now an industry buzzword when it comes to outsourcing and
yet another report adds to the list of research recently published
that give evidence of the increasing popularity of the country as a
location to conduct drug clinical...
The Chinese government has announced plans to consolidate their
outsourcing industry in an effort to capture business from other
developing countries such as India.
A new contract research organization (CRO) has opened in Hong Kong
and will be the only clinical trial site outside of China with the
approval of China's State Food and Drug Administration (SFDA) to
run oncology trials.
China is a big market with a lot of potential but many pharma
industry firms still avoid doing business in the country because of
fears that their intellectual property (IP) cannot be protected.
The rapidly growing market for drug discovery outsourcing services
will increase 15 per cent to reach $7bn (€5.5bn) by 2009, fuelled
by the advancing Asian market, according to a new study by Kalorama
Information, publishing division...
Analytik Jena has started production of its first analytical
apparatus to be made entirely in China representing a new venture
for the company as it aims to advance into a market that has
experienced unprecedented growth in the analytical...
After recently opening up shop in nearby Singapore, SGS has now
brought its contract testing services to neighbouring China to
continue to cash in on the demand for such services in the
Asia-Pacific region.
Looking to add active pharmaceutical ingredients (APIs) and
intermediates to its Chinese portfolio, Degussa has acquired a
majority stake in the Chinese fine chemicals firm Lynchem, allowing
it to target the pharma industry more competitively.
German packaging firm Gerresheimer has ventured further into China,
buying a majority interest in Chinese pharmaceutical packager
Shuangfeng Group and gaining entry into the Chinese market for
tubular glass packaging for the first...
In what it claims is the largest investment to date by any
multinational drug company in China, AstraZeneca will spend $100m
(€77.6m) on research and development in the country over the next
three years, targeting primarily the domestic...
As China improves its resources and regulatory processes it will
soon become a hotbed of clinical drug research activity, and
position itself as one of the world's most important countries in
this field, according to a new report...
Italian processing machinery company IMA Group has decided to
increase its investment in a Chinese joint venture to tap into a
growth market at a time when its established territories in the
West are showing lacklustre growth, reports...
China has defended its decision to overturn Pfizer's patent on its
blockbuster drug for erectile dysfunction, Viagra (sildenafil), in
a ruling that was seen as a blow to hopes that the country would
enforce intellectual property...
A new Sino-American joint venture for manufacturing
pharmaceuticals, HBBenda, has started operations in Guangshui,
China, after being granted Good Manufacturing Practice (GMP)
approval.
